Menu Search
Equities

Akso Health Group

8HX:BER

Akso Health Group

Actions
  • Price (EUR)0.815
  • Today's Change-0.02 / -2.40%
  • Shares traded--
  • 1 Year change-14.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Akso Health Group, formerly Xiaobai Maimai Inc, is a China-based company mainly engaged in e-commerce business. The Company provides services through the Xiaobai Maimai application (APP), a one-stop e-commerce platform. The Company provides products covering food and beverage, wine, cosmetic products, fashion and apparel, entertainment, houseware, home appliances and others. The Company is also engaged in social e-commerce platform business, cancer therapy and radiotherapy oncology service provider business, and the sale of coronavirus disease 2019 (COVID-19) Rapid Antigen Tests.

  • Revenue in USD (TTM)2.41m
  • Net income in USD-9.06m
  • Incorporated2016
  • Employees42.00
  • Location
    Akso Health Group5Th Floor,Block C, Shimao No. 92 Jianguo Road ChaBEIJING 0000ChinaCHN
  • Phone+86 1 053709902
  • Websitehttps://ir.xiaobaimaimai.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.